Galera Therapeutics, Inc. (GRTX)’in fiyatı nedir?

Galera Therapeutics, Inc. (GRTX)’in fiyatı $17.15’dir

Galera Therapeutics, Inc. (GRTX)’in piyasa değeri nedir?

Galera Therapeutics, Inc. (GRTX)’in piyasa değeri $6.51M’dir.

Galera Therapeutics, Inc. (GRTX) Temettüler

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.

Yıl	Temettü (hisse bölünmesiyle ayarlanmış)	Değiştir
Sağlanan tarihler için yeterli veri yok.

Yıl

Temettü (hisse bölünmesiyle ayarlanmış)

Değiştir

Sağlanan tarihler için yeterli veri yok.

Yıl	Temettü	Değiştir
Sağlanan tarihler için yeterli veri yok.

Yıl

Temettü

Değiştir

Sağlanan tarihler için yeterli veri yok.

Şirket	Temettü ödemesi sayısı	Ülke
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	29.00%	BE

Şirket

Temettü ödemesi sayısı

Ülke